European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

From my colleague Andrew Joseph: After a bumpy road, Eisai and Biogen’s Alzheimer’s therapy Leqembi has won approval in ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

On Monday, 74-year-old Ralph Carmona of Portland will be the only qualified Boston Marathon runner with Alzheimer's.